Mutation-Enhanced International Prognostic Score System (MIPSS70/MIPSS70+)
Stratifies risk for patients with overt primary myelofibrosis (PMF).
Be aware, this tool provides results for either MIPSS70 or MIPSS70+, version 2.0, depending on whether karyotype information is available.
- If karyotype is not available, this tool will default to MIPSS70.
- If karyotype information is inputted, the tool will default to MIPSS70+. which will also affect hemoglobin (i.e., more specific anemia cutoff values) and HMR mutation inputs (i.e., the inclusion of U2AR1 Q157).
Advice
- Results may be used alone or to refine the prognosis established from other prognostic models (e.g., GIPSS).
- Use results in conjunction with clinical judgment and patient preference to guide management care plans and inform goals of care discussions.
- Higher-risk patients (high or very high risk designations in MIPSS70+): Consider referral to a transplant center for HSCT evaluation.
- Intermediate-risk patients: Discuss options, including aggressive, experimental, or conservative management, and monitor closely for progression.
- Low-risk patients (low, or very low risk designations in MIPSS70+): Consider conservative, symptom-directed treatment with regular follow-up.
- Results are prognostic, not predictive of treatment response; clinical judgment and specialist consultation remain essential.